Table 1 Demographic and clinical characteristics for the entire study subjects according to ASCT.
Characteristics | Patients, n (%) | |
|---|---|---|
No ASCT (n = 104) | ASCT (n = 123) | |
Male | 61 (58.7) | 66 (53.7) |
Age*, range (median) | 45–90 (69) | 33–74 (57) |
- Younger | 32 (30.8) | 40 (32.5) |
- Intermediate | 37 (35.6) | 42 (34.1) |
- Older | 35 (33.7) | 41 (33.3) |
R-ISS stage | ||
- I | 33 (31.7) | 51 (41.5) |
- II | 52 (50.0) | 53 (43.1) |
- III | 19 (18.3) | 19 (15.4) |
Chemotherapy regimen | ||
- VTD | 21 (20.2) | 70 (56.9) |
- VMP | 45 (43.3) | 3 (2.4) |
- Other three-drug regimens** | 5 (4.8) | 26 (21.1) |
- Miscellaneous | 33 (31.7) | 24 (19.5) |
Radiotherapy | 9 (8.7) | 18 (14.6) |
Hypercalcemia | 8 (7.7) | 20 (16.3) |
Renal insufficiency | 24 (23.1) | 28 (22.8) |
Anemia | 51 (49.0) | 64 (52.0) |
Bone lesion positive | 86 (82.7) | 110 (89.4) |
Extramedullary disease | 21 (20.2) | 16 (13.0) |
FDG parameter*** | ||
- SUVmax, range (median) | 2.5–22.3 (5.7) | 2.5–35.7 (5.5) |
- SUVmean, range (median) | 2.6–6.3 (3.0) | 2.5–7.6 (2.9) |
- MTV, range (median) | 0.10–1255.3 (31.8) | 0.1–1859.2 (33.1) |
- TLG, range (median) | 0.26–5058.9 (115.9) | 0.1–6397.6 (108.8) |
- SUVmax, high | 38 (36.5) | 80 (65.0) |
- SUVmean, high | 37 (35.6) | 52 (42.3) |
- MTV, high | 62 (59.6) | 48 (39.0) |
- TLG, high | 34 (32.7) | 44 (35.8) |
- FL > 3 | 54 (51.9) | 70 (56.9) |